Clinical Trials Logo

Urinary Bladder, Overactive clinical trials

View clinical trials related to Urinary Bladder, Overactive.

Filter by:

NCT ID: NCT00350636 Completed - Overactive Bladder Clinical Trials

A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo

Start date: June 2006
Phase: Phase 3
Study type: Interventional

A new drug for overactive bladder is compared to placebo to determine if it is safe and effective. The study lasts approximately 12 weeks.

NCT ID: NCT00343486 Completed - Overactive Bladder Clinical Trials

Dose Ranging Study Of Solabegron Versus Placebo In Female Patients With Overactive Bladder Symptoms

Start date: May 2006
Phase: Phase 2
Study type: Interventional

This study will test the effectiveness and safety of two doses of solabegron against placebo in reducing the symptoms of overactive bladder.

NCT ID: NCT00337558 Completed - Clinical trials for Urinary Incontinence

A Study of Solifenacin With Bladder Training Versus Solifenacin Alone in Patients With Overactive Bladder (SOLAR)

SOLAR
Start date: May 2006
Phase: Phase 4
Study type: Interventional

This study will look at a drug for OAB (solifenacin) in combination with a non drug treatment (bladder training) compared to the drug on its own. The study will compare the symptoms of OAB by assessing patient diaries and other patient reported outcomes.

NCT ID: NCT00337090 Completed - Overactive Bladder Clinical Trials

A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)

Start date: n/a
Phase: Phase 2
Study type: Interventional

The study will examine which dose of YM178 is best in terms of efficacy, safety and tolerability compared to placebo and compared to tolterodine, a marketed product.

NCT ID: NCT00335660 Terminated - Clinical trials for Overactive Bladder Syndrome

Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity

Start date: June 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the effects of AV608, a neurokinin 1 (NK-1) antagonist, in subjects with Idiopathic Detrusor Overactivity.

NCT ID: NCT00332319 Terminated - Overactive Bladder Clinical Trials

Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladder In Spinal Cord Injury Patients

Start date: January 2006
Phase: Phase 2
Study type: Interventional

This is a two-part study in which Part A will assess the effects of GW679769 after 1 dose on the function of the nerves that supply the bladder. The technique for measuring the nerves function is called Neurometry. Part B will assess the effect of repeat doses of GW679769 on the bladder nerve function. Part B will also assess the effects of the drug on overactive bladder symptoms using a three-day patient diary.

NCT ID: NCT00321477 Completed - Overactive Bladder Clinical Trials

A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder

Start date: December 2005
Phase: Phase 2
Study type: Interventional

This is a Phase IIa study to evaluate the efficacy, safety and tolerability of GW679769 vs placebo on symptoms of urgency with urge incontinence, frequency and nocturia associated with overactive bladder in women.

NCT ID: NCT00313924 Recruiting - Overactive Bladder Clinical Trials

Assessing the OAB-8 Questionnaire as a Tool to Measure Treatment Outcome

Start date: February 2006
Phase: Phase 4
Study type: Interventional

OAB is a widespread medical problem affecting 6- 30% of the population (both sexes and all age groups) in Europe1 and 16%2-18%3 of the US and Canadian population. Nevertheless only a small proportion of this group turns to seek medical help. Once treated, evaluation of treatment outcome is problematic since outcome measures for success vary widely (i.e. improvement in number of incontinence episodes, number of urge episodes, change in frequency and nocturia etc) but do not include measures of patient reported outcomes. The OAB Assessment Tool is a self-administered questionnaire (8-question self–filled survey) primarily intended to identify patients with symptoms of OAB. The same comparable information could be obtained after a certain treatment period, thus providing accurate and precise measures of success. It could also offer insight to the changes of the different parameters that make up the problem. Due to its ease of administration and its high specificity in assessing OAB, the OAB Assessment Tool seems to be optimal for this objective.

NCT ID: NCT00311376 Completed - Overactive Bladder Clinical Trials

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

Start date: August 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A in treating overactive bladder in spinal cord injury or multiple sclerosis patients.

NCT ID: NCT00293839 Completed - Clinical trials for Urinary Incontinence

Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder

Start date: n/a
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy of DITROPAN® XL (oxybutynin chloride) Extended-Release Tablets and DETROL® LA (tolterodine tartrate extended-release capsules) in the reduction of urge urinary incontinence episodes during a 12-week treatment period in patients with overactive bladder. The secondary objective is to compare the tolerability of DITROPAN® XL (oxybutynin chloride) and DETROL® LA (tolterodine tartrate) during a 12-week treatment period.